Aerovate Therapeutics Stock EBITDA
| AVTE Stock | USD 2.58 0.15 6.17% |
Aerovate Therapeutics fundamentals help investors to digest information that contributes to Aerovate Therapeutics' financial success or failures. It also enables traders to predict the movement of Aerovate Stock. The fundamental analysis module provides a way to measure Aerovate Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aerovate Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -73.2 M | -69.5 M |
Aerovate | EBITDA |
Aerovate Therapeutics Company EBITDA Analysis
Aerovate Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Aerovate Therapeutics EBITDA | (81.31 M) |
Most of Aerovate Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aerovate Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aerovate EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Aerovate Therapeutics is extremely important. It helps to project a fair market value of Aerovate Stock properly, considering its historical fundamentals such as EBITDA. Since Aerovate Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aerovate Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aerovate Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Aerovate Ebitda
Ebitda |
|
According to the company disclosure, Aerovate Therapeutics reported earnings before interest,tax, depreciation and amortization of (81.31 Million). This is 109.27% lower than that of the Biotechnology sector and 181.19% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.09% higher than that of the company.
Aerovate EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aerovate Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aerovate Therapeutics could also be used in its relative valuation, which is a method of valuing Aerovate Therapeutics by comparing valuation metrics of similar companies.Aerovate Therapeutics is currently under evaluation in ebitda category among its peers.
Aerovate Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aerovate Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aerovate Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aerovate Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aerovate Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aerovate Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aerovate Therapeutics' value.| Shares | Gsa Capital Partners Llp | 2024-09-30 | 413.8 K | Ikarian Capital, Llc | 2024-09-30 | 368 K | State Street Corp | 2024-09-30 | 367.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 334 K | Two Sigma Investments Llc | 2024-09-30 | 313.1 K | Geode Capital Management, Llc | 2024-09-30 | 291.9 K | Bank Of America Corp | 2024-09-30 | 261 K | Citigroup Inc | 2024-09-30 | 233.4 K | Millennium Management Llc | 2024-09-30 | 196.6 K | Ra Capital Management, Llc | 2024-09-30 | 9.2 M | Sofinnova Ventures | 2024-09-30 | 3.8 M |
Aerovate Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (13.6 M) | ||||
| Shares Outstanding | 28.91 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 99.99 % | ||||
| Number Of Shares Shorted | 2.52 M | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 0.93 X | ||||
| EBITDA | (81.31 M) | ||||
| Net Income | (75.52 M) | ||||
| Cash And Equivalents | 151.99 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 675 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 40.85 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (56.78 M) | ||||
| Short Ratio | 14.30 X | ||||
| Earnings Per Share | (3.17) X | ||||
| Target Price | 2.5 | ||||
| Number Of Employees | 51 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 74.59 M | ||||
| Total Asset | 127.42 M | ||||
| Retained Earnings | (163.42 M) | ||||
| Working Capital | 106.59 M | ||||
| Net Asset | 127.42 M |
About Aerovate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aerovate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aerovate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aerovate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Aerovate Therapeutics Piotroski F Score and Aerovate Therapeutics Altman Z Score analysis. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.